Search | Clinical Trials Finder

Conditions: Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma
Interventions: Indoximod, Ipilimumab, Nivolumab, Pembrolizumab; Drug
Lead sponsor: NewLink Genetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 6
States / cities: Augusta, Georgia • Iowa City, Iowa • Rochester, Minnesota + 3 more

Conditions: Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer
Interventions: cabozantinib, atezolizumab; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 914 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 57
States / cities: Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more

Conditions: Hepatocellular Carcinoma, Biliary Tract Cancer
Interventions: RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy; Biological
Lead sponsor: Replimune, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 12
States / cities: Beverly Hills, California • La Jolla, California • Miami, Florida + 9 more

Conditions: Head and Neck Cancer, Non-Small Cell Lung Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer (GC)
Interventions: Stereotactic Body Radiation Therapy (SBRT), Pembrolizumab, Nivolumab, Atezolizumab, Ipilimumab; Radiation · Drug
Lead sponsor: Mark Bernard; Other
Eligibility: 18 Years to 99 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2040
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Breast Cancer
Interventions: HCQ, Avelumab, Palbociclib; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Indianapolis, Indiana + 4 more

Conditions: Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue, Metastatic Malignant Neoplasm in the Viscera, Rhabdoid Tumor of the Kidney, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 858
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 554 more

Conditions: Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer, Renal Carcinoma, Kidney Cancer Metastatic
Interventions: Olaparib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-Negative Breast Carcinoma, Node-positive Breast Cancer
Interventions: Neoadjuvant Pembrolizumab, low dose neoadjuvant boost, High dose neoadjuvant boost; Drug · Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Advanced/Metastatic NSCLC
Interventions: Immunotherapy - PD-1 Blocker; Drug
Lead sponsor: Liza Villaruz, MD; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Patients With Non-Small Cell Lung Cancer
Interventions: OSE2101, Docetaxel, NGS HLAA2 assay; Drug · Device
Lead sponsor: OSE Immunotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 79
States / cities: Beverly Hills, California • Encino, California • Los Angeles, California + 56 more

Conditions: Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV, Drug-Induced Colitis, Drug Toxicity, Immune-related Adverse Event
Interventions: Infliximab, Methylprednisolone, Prednisone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cancer, Skin Disease, Immunotherapy, Patients With Solid Tumors Receiving Immunotherapy With an ICI Will be Randomized to Participate in an SDoH and Side Effects Navigation Program vs. Control
Interventions: systemic corticosteroid or biologic; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Denver, Colorado • New York, New York

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions: Ipilimumab, Pembrolizumab, Vaccine Therapy; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
Interventions: TILT-123, pembrolizumab, pegylated liposomal doxorubicin; Biological · Drug
Lead sponsor: TILT Biotherapeutics Ltd.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Rochester, Minnesota • New York, New York

Conditions: Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Interventions: Nadofaragene Firadenovec, Gemcitabine, Docetaxel, Pembrolizumab; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 40
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more

Conditions: Cancer
Interventions: Non-Interventional; Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma, Unresectable Stage III Non-Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Stage IV Merkel Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma, Stage IV Basal Cell Carcinoma, Stage IV Breast Cancer, Stage IV Colorectal Cancer, Stage IV Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Hepatocellular Cancer, Stage IV Renal Cell Carcinoma, Stage IV Bladder Cancer, Stage IV Head and Neck Squamous Cell Carcinoma, Stage IV Cervical Cancer, Stage IV Endometrial Cancer, Stage IV Mesothelioma, Immunotherapy, Immune Checkpoint Inhibitors
Interventions: Educational Video and QPL List, Usual Care; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Non-Interventional Study; Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Melanoma, Gastrointestinal Neoplasms, Genitourinary Cancer, Thoracic Cancer, Sarcoma
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma
Interventions: Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy; Combination Product · Drug
Lead sponsor: PDS Biotechnology Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 28
States / cities: Phoenix, Arizona • Greenbrae, California • Orange, California + 24 more

Conditions: Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Antineoplastic Immune Cell, Atezolizumab, Biospecimen Collection, Cyclophosphamide, Fludarabine; Biological · Procedure · Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Orange, California

Conditions: Lung Cancer Stage IV
Interventions: Blood and tumor tissue analysis, Clinical response.; Other
Lead sponsor: Holy Cross Hospital, Maryland; Other
Eligibility: 18 Years to 70 Years
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Metastatic Cancer, Solid Tumors
Interventions: SX-682, M7824, MVA-BN-CV301, recombinant fowlpox viral (FPV)-CV301; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib Hydrochloride, Echocardiography Test, Ipilimumab, Nivolumab, X-Ray Imaging; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 5
States / cities: Boston, Massachusetts • Austin, Texas • Galveston, Texas + 2 more

Search by objective public record fields.

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer

Impact of Circadian Rhythm on Immunotherapy

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

Observational Study of Sex Differences in Symptoms During Immune Checkpoint Inhibitor Treatment for People With Cancer

Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Personalizing Immune Checkpoint Inhibitor Therapy

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN